Study Finds Elekta MRI-Guided Adaptive Radiotherapy Improves Quality of Life in Prostate Cancer Patients

A new study shows that Elekta’s MRI-guided adaptive radiation therapy system, Elekta Unity (EKTA-B.ST), significantly improves urinary symptoms and overall quality of life for men with localized prostate cancer.

The results, presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, come from the international MOMENTUM registry (NCT04075305). The study followed 630 patients treated across 12 centers in North America and Europe. Patients received five treatment sessions over two weeks, with half undergoing standard MR-guided therapy and half receiving adaptive treatment that accounted for daily changes in prostate anatomy.

Findings revealed that the adaptive approach led to sustained improvements in urinary irritation symptoms over one year. Researchers say this is due to Unity’s ability to track anatomical changes during treatment, allowing clinicians to tailor radiation delivery in realtime.

Dr. William A. Hall, Chair of Radiation Oncology at the Medical College of Wisconsin, emphasized that Unity makes previously unseen anatomical shifts visible, “One of the most surprising results of our analysis was just how much the prostate changes shape during treatment. As a clinician who cares for prostate cancer patients, I am very reassured that with Unity I can do something about these changes.”

Elekta’s Senior Vice President of Medical Affairs, Dr. John Christodouleas, added that the work highlights the power of collaboration among clinicians and researchers worldwide, “This study represents an important contribution to our understanding of what is happening during prostate cancer radiation and how we can preserve a man’s quality of life after treatment.”